Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BYSINASDAQ:KZRNASDAQ:LXEONASDAQ:LYEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBYSIBeyondSpring$2.52+0.4%$1.99$0.98▼$3.44$101.19M0.0732,333 shs19,596 shsKZRKezar Life Sciences$4.27+4.4%$4.29$3.62▼$9.18$29.88M0.5856,505 shs92,864 shsLXEOLexeo Therapeutics$4.18-0.2%$3.49$1.45▼$19.50$139.10M0.52535,134 shs442,159 shsLYELLyell Immunopharma$9.12-1.8%$9.12$7.65▼$38.40$137.57M-0.2668,021 shs71,461 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBYSIBeyondSpring+0.40%-18.97%+44.91%+75.00%+3.28%KZRKezar Life Sciences+4.40%-4.26%+11.49%-13.21%-32.34%LXEOLexeo Therapeutics-0.24%-1.42%+54.81%+1.95%-71.45%LYELLyell Immunopharma-1.83%-4.80%+11.06%-15.74%-65.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBYSIBeyondSpringN/AN/AN/AN/AN/AN/AN/AN/AKZRKezar Life Sciences4.2652 of 5 stars3.25.00.04.60.62.50.6LXEOLexeo Therapeutics2.4209 of 5 stars3.52.00.00.01.32.50.6LYELLyell Immunopharma3.5056 of 5 stars2.83.00.00.03.05.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBYSIBeyondSpring 0.00N/AN/AN/AKZRKezar Life Sciences 2.33Hold$39.50825.06% UpsideLXEOLexeo Therapeutics 3.00Buy$16.60297.13% UpsideLYELLyell Immunopharma 1.50Reduce$15.0064.47% UpsideCurrent Analyst Ratings BreakdownLatest KZR, LXEO, LYEL, and BYSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$10.005/30/2025LXEOLexeo TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $10.005/16/2025LXEOLexeo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $15.005/13/2025LXEOLexeo TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $20.004/16/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$20.00 ➝ $20.004/8/2025LXEOLexeo TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $22.004/8/2025LXEOLexeo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBYSIBeyondSpring$1.75M58.06N/AN/A($0.37) per share-6.81KZRKezar Life Sciences$7M4.46N/AN/A$16.02 per share0.27LXEOLexeo Therapeutics$650K213.50N/AN/A$3.53 per share1.18LYELLyell Immunopharma$60K2,251.12N/AN/A$26.21 per share0.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBYSIBeyondSpring-$11.12MN/A0.00∞N/AN/AN/AN/AN/AKZRKezar Life Sciences-$83.74M-$10.82N/AN/AN/AN/A-61.15%-50.27%8/12/2025 (Estimated)LXEOLexeo Therapeutics-$98.33M-$3.30N/AN/AN/AN/A-85.86%-68.48%8/11/2025 (Estimated)LYELLyell Immunopharma-$342.99M-$25.00N/AN/AN/A-514,649.22%-73.66%-60.99%8/6/2025 (Estimated)Latest KZR, LXEO, LYEL, and BYSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025KZRKezar Life Sciences-$2.56-$2.27+$0.29-$2.27N/AN/A5/13/2025Q1 2025LYELLyell Immunopharma-$3.80-$3.60+$0.20-$0.18N/A$0.01 million5/12/2025Q1 2025BYSIBeyondSpringN/A-$0.06N/A$0.11N/AN/A5/12/2025Q1 2025LXEOLexeo Therapeutics-$0.80-$0.99-$0.19-$0.99N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBYSIBeyondSpringN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBYSIBeyondSpringN/A2.492.49KZRKezar Life Sciences0.047.097.09LXEOLexeo Therapeutics0.013.423.42LYELLyell ImmunopharmaN/A7.497.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBYSIBeyondSpring40.29%KZRKezar Life Sciences67.90%LXEOLexeo Therapeutics60.67%LYELLyell Immunopharma66.05%Insider OwnershipCompanyInsider OwnershipBYSIBeyondSpring29.31%KZRKezar Life Sciences10.40%LXEOLexeo Therapeutics5.30%LYELLyell Immunopharma22.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBYSIBeyondSpring8040.32 million28.50 millionOptionableKZRKezar Life Sciences607.31 million6.55 millionNot OptionableLXEOLexeo Therapeutics5833.20 million31.44 millionNot OptionableLYELLyell Immunopharma27014.81 million11.51 millionOptionableKZR, LXEO, LYEL, and BYSI HeadlinesRecent News About These CompaniesLyell Immunopharma (NASDAQ:LYEL) Price Target Raised to $10.00 at HC WainwrightJune 25 at 2:12 AM | americanbankingnews.comLyell Immunopharma (NASDAQ:LYEL) Stock Price Expected to Rise, HC Wainwright Analyst SaysJune 24 at 8:18 AM | marketbeat.comLyell Immunopharma (NASDAQ:LYEL) Trading 3.5% Higher - Here's What HappenedJune 24 at 2:45 AM | americanbankingnews.comLyell Immunopharma (NASDAQ:LYEL) Trading 3.5% Higher - What's Next?June 24 at 2:41 AM | marketbeat.comLyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" SeriesJune 23, 2025 | tmcnet.comLyell Immunopharma to Discuss Clinical Data on LYL314 at H.C. Wainwright's "HCW@Home" SeriesJune 23, 2025 | quiverquant.comQLyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” SeriesJune 23, 2025 | globenewswire.comLyell Immunopharma Releases Data From Phase I/II Trial of CD19/20 Dual Targeting CAR T-Cell TherapyJune 20, 2025 | precisionmedicineonline.comPLyell reports new clinical data from trial of large B-cell lymphoma therapyJune 18, 2025 | finance.yahoo.comLyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell LymphomaJune 17, 2025 | globenewswire.comShort Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Drops By 94.5%June 11, 2025 | marketbeat.comLyell Immunopharma Taps Shook as Chief Medical OfficerJune 11, 2025 | marketwatch.comLyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive AppointmentsJune 9, 2025 | globenewswire.comLyell Immunopharma (NASDAQ:LYEL) Upgraded by Wall Street Zen to "Hold" RatingJune 6, 2025 | marketbeat.comLyell Immunopharma to Participate in the Goldman Sachs Global Healthcare ConferenceJune 4, 2025 | globenewswire.comLyell Immunopharma (NASDAQ:LYEL) Shares Up 14.7% - Should You Buy?June 4, 2025 | marketbeat.comLyell Immunopharma (NASDAQ:LYEL) Hits New 52-Week Low - Here's What HappenedJune 2, 2025 | marketbeat.comShort Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Expands By 71.6%June 1, 2025 | marketbeat.comLyell Immunopharma trading halted, news pendingMay 31, 2025 | msn.comLyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025May 17, 2025 | finanznachrichten.deLyell Immunopharma Advances CAR T-Cell Therapy PipelineMay 13, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKZR, LXEO, LYEL, and BYSI Company DescriptionsBeyondSpring NASDAQ:BYSI$2.52 +0.01 (+0.40%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.49 -0.03 (-1.19%) As of 06/26/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Kezar Life Sciences NASDAQ:KZR$4.27 +0.18 (+4.40%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$4.25 -0.02 (-0.47%) As of 06/26/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Lexeo Therapeutics NASDAQ:LXEO$4.18 -0.01 (-0.24%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$4.19 +0.01 (+0.24%) As of 06/26/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Lyell Immunopharma NASDAQ:LYEL$9.12 -0.17 (-1.83%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$9.10 -0.02 (-0.22%) As of 06/26/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
